Top

Cancer Chemotherapy and Pharmacology

Published in:

01-10-2017 | Original Article

MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells

Authors: Azam Rajabpour, Ali Afgar, Habibollah Mahmoodzadeh, Jalal-e-Din Radfar, Farzad Rajaei, Ladan Teimoori-Toolabi

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2017

Abstract

Purpose

Gemcitabine resistance is the main problem in pancreatic adenocarcinoma patients. Hence, we aimed to identify the correlation between expression of RRM1 and CDA as the resistance genes and their predicted targeting miR-608 in the resistant pancreatic cancer cell lines to gemcitabine.

Methods

Dual luciferase assay was performed to determine whether both RRM1 and CDA are targeted by miR-608 in 293T and pancreatic cancer cell lines. AsPC-1 and MIA PaCa-2 cell lines became gradually resistant to gemcitabine by exposing to the increasing doses of gemcitabine. After RNA and miRNAs extraction and cDNA conversion, the expressions of RRM1, CDA and miR-608 in all cell lines were studied by quantitative PCR. Pre-miR-608 transfection to the cell lines was done by calcium phosphate method. MTT assay was performed for analyzing the chemo sensitivity of different cell lines to gemcitabine.

Results

Luciferase assays showed that miR-608 targeted RRM1 and CDA genes in 293T, AsPC-1 and MIA PaCa-2 cell lines. Compared to parental cell line, resistant MIA PaCa-2 and AsPC-1 cells demonstrated increased expression of RRM1 and CDA. On the other hand the expression of miR-608 in resistant MIA PaCa-2 and AsPC-1 cells was lower than parental cells. Furthermore, transfection of MIA PaCa-2 and AsPC-1 cells by miR-608 lead to decreased expression of RRM1 and CDA and lowered viability of the cells in comparison with scrambled microRNA transfected cells.

Conclusion

During resistance induction in pancreatic cancer cells, miR-608 which is targeting RRM1 and CDA is downregulated which leads to upregulation of these genes.

Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M (2011) Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15(7):817–828CrossRefPubMedPubMedCentral

Valsecchi ME, Holdbrook T, Leiby BE, Pequignot E, Littman SJ, Yeo CJ, Brody JR, Witkiewicz AK (2012) Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer 12(1):1CrossRef

Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T (2010) Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12(10):807–808CrossRefPubMedPubMedCentral

Hagmann W, Jesnowski R, Löhr JM (2010) Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 12(9):740–747CrossRefPubMedPubMedCentral

Rajabpour A, Rajaei F, Teimoori-Toolabi L (2016) Molecular alterations contributing to pancreatic cancer chemoresistance. Pancreatology 17(2):310–320CrossRefPubMed

Rukov JL, Shomron N (2011) MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol Med 17(8):412–423CrossRefPubMed

Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R (2011) CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Can Res 71(5):1825–1835CrossRef

Ueno H, Kiyosawa K, Kaniwa N (2007) Pharmacogenomics of gemcitabine: Can genetic studies lead to tailor-made therapy? Br J Cancer 97(2):145–151CrossRefPubMedPubMedCentral

Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y (2007) Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96(3):457–463CrossRefPubMedPubMedCentral

10.

Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98(10):1710–1715CrossRefPubMedPubMedCentral

11.

Jordheim LP, Dumontet C (2013) Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? Biomarkers 7(4):663–671CrossRef

12.

Jordheim LP, Sève P, Trédan O, Dumontet C (2011) The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 12(7):693–702CrossRefPubMed

13.

Elnaggar M, Giovannetti E, Peters GJ (2012) Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr Pharm Des 18(19):2811–2829CrossRefPubMed

14.

Carpi FM, Vincenzetti S, Ubaldi J, Pucciarelli S, Polzonetti V, Micozzi D, Mignini F, Napolioni V (2013) CDA gene polymorphisms and enzyme activity: genotype–phenotype relationship in an Italian-Caucasian population. Pharmacogenomics 14(7):769–781CrossRefPubMed

15.

Sugiyama E, Kaniwa N, Kim S-R, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, J-i Sawada, Kamatani N (2006) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25(1):32–42CrossRef

16.

Funamizu N, Okamoto A, Kamata Y, Misawa T, Uwagawa T, Gocho T, Yanaga K, Manome Y (2010) Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase? Oncol Rep 23(2):471PubMed

17.

Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N (2013) Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 15:648–659CrossRefPubMedPubMedCentral

18.

Hashimoto Y, Akiyama Y, Yuasa Y (2013) Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS ONE 8(5):e62589CrossRefPubMedPubMedCentral

19.

Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ (2010) Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 3(1):1CrossRef

20.

Hwang J-H, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim Y-T, Funel N, Park JK, Kim MA, Kang GH (2010) Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5(5):e10630CrossRefPubMedPubMedCentral

21.

Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, DeSano JT, Bommer GT, Fan D (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4(8):e6816CrossRefPubMedPubMedCentral

22.

Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Can Res 69(16):6704–6712CrossRef

23.

Park J-K, Lee EJ, Esau C, Schmittgen TD (2009) Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38(7):e190–e199CrossRefPubMed

24.

Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120(6):1355–1363CrossRefPubMed

25.

Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P, Zeinali S (2014) MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther 15(4):419–427CrossRefPubMedPubMedCentral

26.

Gheidari F, Bakhshandeh B, Teimoori-Toolabi L, Mehrtash A, Ghadir M, Zeinali S (2014) TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug. Anticancer Drugs 25(8):908–916CrossRefPubMed

27.

Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Can Res 64(11):3761–3766CrossRef

28.

Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V, Fontana A, Boggi U, Del Chiaro M, Danesi R (2005) Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 93(1):35–40CrossRefPubMedPubMedCentral

29.

Liu X, Wang W, Lin L, Song S (2010) Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines. Zhonghua Zhong Liu Za Zhi [Chin J Oncol] 32(1):17–21

30.

Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res 2(9):807–813CrossRef

31.

Zheng J, Deng J, Xiao M, Yang L, Zhang L, You Y, Hu M, Li N, Wu H, Li W (2013) A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma. Can Res 73(16):5151–5162CrossRef

32.

Ma X-P, Yu G, Chen X, Xiao Q, Shi Z, Zhang L-Y, Chen H, Zhang P, Ding D-L, Huang H-X (2016) MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma. Tumor Biol 37(7):9931–9942CrossRef

33.

Ryan BM, McClary AC, Valeri N, Robinson D, Paone A, Bowman ED, Robles AI, Croce C, Harris CC (2012) rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS ONE 7(5):e36306CrossRefPubMedPubMedCentral

34.

Huang A-J, Yu K-D, Li J, Fan L, Shao Z-M (2012) Polymorphism rs4919510: C > G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. PLoS ONE 7(5):e35252CrossRefPubMedPubMedCentral

35.

Alves R, Antunes F, Salvador A (2006) Tools for kinetic modeling of biochemical networks. Nat Biotechnol 24(6):667–672CrossRefPubMed

36.

Wang S, Raghavachari S (2011) Quantifying negative feedback regulation by micro-RNAs. Phys Biol 8(5):055002CrossRefPubMedPubMedCentral

37.

Raj A, van Oudenaarden A (2008) Nature, nurture, or chance: stochastic gene expression and its consequences. Cell 135(2):216–226CrossRefPubMedPubMedCentral

38.

Pedraza JM, van Oudenaarden A (2005) Noise propagation in gene networks. Science 307(5717):1965–1969CrossRefPubMed

39.

Bhardwaj V, Bhushan A, Lai JC, Tadinada SM (2012) Failure of pancreatic cancer chemotherapy: consequences of drug resistance mechanisms. INTECH Open Access Publisher, Rijeka

40.

Azmi AS, Beck FW, Bao B, Mohammad RM, Sarkar FH (2011) Aberrant epigenetic grooming of miRNAs in pancreatic cancer:a systems biology perspective. Epigenomics 3(6):747–759CrossRefPubMedPubMedCentral

41.

Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R (2004) Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95(9):753–757CrossRefPubMed

42.

Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16(1):43–51CrossRefPubMed

43.

Kasinski AL, Slack FJ (2011) MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11(12):849–864CrossRefPubMedPubMedCentral

Title: MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells
Authors: Azam Rajabpour
Ali Afgar
Habibollah Mahmoodzadeh
Jalal-e-Din Radfar
Farzad Rajaei
Ladan Teimoori-Toolabi
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3418-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2017

Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy

Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition

Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer

Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?

Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect

Keynote webinar | Spotlight on antibody–drug conjugates in cancer